Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein. (April 2014)

• Record Type: Journal Article
• Authors: Khazardoost, Soghra; Mousavi, Sanaz; Borna, Sedigheh; Hantoushzadeh, Sedigheh; Alavi, Azin; Khezerlou, Naser
• Is Part Of: Journal of maternal-fetal & neonatal medicine. Volume 27:Number 6(2014:Jun.)
• Page Start: 561
• Page End: 565
• Publication Date: 2014-04
• Subjects: Obstetrics -- Periodicals; Perinatology -- Periodicals; Infants (Newborn) -- Diseases -- Periodicals; Neonatology -- Periodicals; 618.2
• DOI: 10.3109/14767058.2013.822483
• Languages: English
• ISSNs: 1476-7058

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background</italic>: To evaluate the effect of low-dose aspirin in prevention of adverse pregnancy outcomes (APO) in women with second trimester alpha-fetoprotein (AFP) >2.5 multiple of median (MOM) and to compare aspirin effect on women with normal and abnormal uterine artery (UtA) Doppler. The primary outcome was the adverse pregnancy outcome.</p> <p> <italic>Methods</italic>: This randomized controlled trial was conducted in singleton pregnant women, who had unexplained AFP >2.5 MOM and gestational age between 15 and 18 weeks of gestation. They were assigned randomly to receive either aspirin (<italic>N</italic> = 65) or control (<italic>N</italic> = 68). UtA Doppler velocimetry studies were performed at the time of targeted ultrasonographic exam.</p> <p> <italic>Results</italic>: Two groups were comparable regarding the maternal characteristics. The frequency of APO in aspirin and control groups were 26.1% versus 44.1% (<italic>p</italic> = 0.045), the frequency of preterm delivery before 34 weeks were 3.2% versus 22.0% in aspirin and control group, <italic>p</italic> = 0.001. Other outcomes were similar in both groups. The frequency of adverse outcomes in women with abnormal UtA Doppler was 39.1% in aspirin and 60.0% in control group, <italic>p</italic> = 0.556.</p> <p> <italic>Conclusion</italic>: Low-dose aspirin reduces APO and delivery before 34 weeks of gestation in pregnant women with unexplained elevated AFP.</p> </abstract>